Crescera Capital
Crescera Capital is a venture capital firm based in Rio De Janeiro, Brazil, focused on Seed, Series A, and Late Stage startups in SaaS & Enterprise, Artificial Intelligence, and Healthcare & Biotech. This profile covers its focus and how founders can get in front of it in 2026.
Crescera Capital is a investment firm that focuses on private equity and venture capital.
- Investment focus
- SaaS & EnterpriseArtificial IntelligenceHealthcare & BiotechEdTechConsumer & RetailMobility & Logistics
- Investment stages
- SeedSeries ALate Stage
- Location
- Rio De Janeiro, Brazil
- Founded
- 2008
- Team size
- 11-50
- Portfolio companies
- 84+
About Crescera Capital
Crescera Investimentos is an alternative asset management firm created by the merger of the Bozano Group with three leading and complementary investment firms, BR Investimentos, Mercatto Gestão de Recursos and Trapezus Asset Management, resulting in a unique platform for investors, clients and partners. Structured as a partnership, Crescera Investimentos is able to attract, retain and develop the best talents in each specialty.
Our investment philosophy builds on trust and knowledge. We offer to our clients, investors and investees companies consistent and distinguished returns through diversified financial products and strategies. Founded with approximately R$ 4 billion in AUM, Bozano Investimentos aims to become the most successful alternative investment management firm in Latin America.
BR Investimentos` private equity business combines industry knowledge and specialized teams in well-defined circles of competence to successfully invest in privately held Brazilian growth companies. Mercatto Gestão de Recursos has been delivering solid returns through its managed public equities and fixed income portfolios based on strictly fundamental analysis.
Source: the organization's public company profile.
How to pitch Crescera Capital
The founders who hear back from Crescera Capital lead with traction and a clear ask that matches its stage, not a generic mass email. Build a targeted, verified list, write a personalized note, and track who opens it, all in one place.
Connect with Crescera Capital
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Crescera Capital." Round Funded investor database, updated October 19, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/vc/crescera-capital
Frequently Asked Questions
What does Crescera Capital invest in?
Crescera Capital focuses on SaaS & Enterprise, Artificial Intelligence, Healthcare & Biotech, and EdTech. Match your sector and stage before reaching out, then find similar active investors on Round Funded.
What stage does Crescera Capital invest at?
Crescera Capital focuses on Seed, Series A, and Late Stage rounds. Lead with traction that fits the stage when you reach out.
Is Crescera Capital actively investing?
Yes. Round Funded's research found that Crescera Capital has made a new investment or run a new cohort since 2024. Reach out with a personalized pitch that fits its stage and focus, then track who opens it.
Where is Crescera Capital based?
Crescera Capital is based in Rio De Janeiro, Brazil. You can reach out from anywhere with a pitch that matches its focus.
How do I contact Crescera Capital?
Unlock a verified email for Crescera Capital and reach out with a personalized pitch on Round Funded. We show only deliverable contacts, so your outreach does not bounce.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.